Nasdaq Markets

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

In trading on Monday, oil & gas exploration & production shares were relative laggards, down on the day by about 2.4%. Helping drag down the group were shares of Chesapeake Energy, off about 26% and shares of Denbury Resources off about 17.3% on the day.

Seagate Technology (NASDAQ: STX) recently posted strong third-quarter numbers that surpassed Wall Street's expectations. The hard drive maker's revenue rose 18% annually to $2.72 billion, beating estimates by $80 million and breaking a five-quarter streak of declines. Its non-GA

An experimental treatment in late-stage development hit a bullseye in a clinical trial with Alzheimer's disease patients. Axsome Therapeutics' (NASDAQ: AXSM) lead treatment candidate, AXS-05 significantly reduced symptoms of Alzheimer's disease agitation during the pivotal Adva

Starbucks (NASDAQ: SBUX) announced that it's partnering with venture capital firm Sequoia Capital to invest in Chinese tech companies in the food and retail industries.

In trading on Monday, shares of First Republic Bank (Symbol: FRC) crossed above their 200 day moving average of $102.21, changing hands as high as $102.24 per share. First Republic Bank shares are currently trading up about 2% on the day. The chart below shows the one year

In trading on Monday, shares of Green Dot Corp (Symbol: GDOT) crossed above their 200 day moving average of $29.20, changing hands as high as $29.79 per share. Green Dot Corp shares are currently trading up about 4.6% on the day. The chart below shows the one year performanc

(RTTNews) - General Motors Co. (GM) said it has suspended the quarterly cash dividend and its share repurchase program. It has taken other significant austerity measures to preserve near-term available cash.

Shares of Arcturus Therapeutics Holdings Inc. (ARCT) soared after the company reported positive immunogenicity data from the preclinical study of its COVID-19 vaccine candidate.

The stock jumped 24% to $28.01 in midday U.S. trading. Arcturus said that the early data results for its vaccine candidate, known as LUNAR-COV19 support the start of human clinical trials this summer and indicate that it has the potential to immunize millions of people.

San Diego-based Arcturus is a clinical stage company focused on ribonucleic acid (RNA) medicines and vaccines and has developed an internal messenger RNA platform. It specializes in the discovery, development and commercialization of therapeutics for rare diseases and vaccines.

The LUNAR-COV19 preclinical study was conducted by Duke-NUS Medical School in Singapore.

“These preclinical studies done in partnership with Arcturus establish a strong package of data to support initiation of human clinical trials this summer,” said Professor Ooi Eng Eong, Deputy Director of the Emerging Infectious Diseases Programme at Duke-NUS Medical School. “There is a tremendous urgency to develop an effective vaccine in this global fight against COVID-19.”

The study results showed that self-transcribing and replicating (STARR) mRNA induced higher seroconversion relative to conventional mRNA at equivalent doses. In addition, the study found that 100% of animals seroconverted by day 19 at a low dose.

“These data show that Arcturus’ STARR mRNA is superior to conventional mRNA at all equivalent doses and timepoints,” said Pad Chivukula, Chief Scientific Officer at Arcturus. “Selfreplicating mRNA significantly increases spike protein expression, yielding many-fold higher seroconversion rates. The results at the 2 µg dose suggest LUNAR-COV19 has the potential to immunize millions more people.”

All in all, Arcturus stock has a resounding Buy rating from the 5 Wall Street analysts covering the company in the past three months resulting in a Strong Buy consensus. Following Monday’s stock surge, the $23.40 average price target now indicates a potential downside of about 17% from current levels. (See Arcturus stock analysis on TipRanks).

Related News:
GameStop Pops 6% As Activist Hestia Capital Urges Shareholders To Vote For Change
What To Watch For In Pfizer’s 1Q20 Earnings Tomorrow
Gilead Shares Dip on Leaked Trial Data Showing No ‘Benefit’ of Antiviral Drug

In trading on Monday, shares of Takeda Pharmaceutical Co Ltd (Symbol: TAK) crossed above their 200 day moving average of $18.04, changing hands as high as $18.65 per share. Takeda Pharmaceutical Co Ltd shares are currently trading up about 6.2% on the day. The chart below sh

In trading on Monday, shares of Haemonetics Corp. (Symbol: HAE) crossed above their 200 day moving average of $117.54, changing hands as high as $118.59 per share. Haemonetics Corp. shares are currently trading up about 1.2% on the day. The chart below shows the one year per

In trading on Monday, shares of Thor Industries, Inc. (Symbol: THO) crossed above their 200 day moving average of $61.02, changing hands as high as $61.91 per share. Thor Industries, Inc. shares are currently trading up about 6.1% on the day. The chart below shows the one ye

In trading on Monday, shares of Laboratory Corporation of America Holdings (Symbol: LH) crossed above their 200 day moving average of $165.86, changing hands as high as $174.90 per share. Laboratory Corporation of America Holdings shares are currently trading up about 6% on t

In trading on Monday, shares of the iShares Ultra Short-Term Bond ETF (Symbol: ICSH) crossed above their 200 day moving average of $50.30, changing hands as high as $50.32 per share. iShares Ultra Short-Term Bond shares are currently trading trading flat on the day. The char

(RTTNews) - Following the advance seen last Friday, stocks have seen some further upside over the course of morning trading on Monday. With the upward move, the tech-heavy Nasdaq has reached its best intraday level in well over a month.

Liberty SiriusXM Group (NASDAQ: LSXMA)(NASDAQ: LSXMK) (NASDAQ: LSXMB) is one of three tracking stocks within Liberty Media. It also has The Liberty Braves Group and Formula One Group. Tracking stocks are not common, so let's define them. According to Liberty Media's annual repor

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:

The Zacks Biomedical And Genetics industry includes biopharmaceutical and biotechnology companies that develop high-profile drugs. These biologically processed drugs, addressing virology, neuroscience, metabolism and rare diseases, are manufactured using live organisms. The main

Molson Coors Beverage Company TAP is slated to release first-quarter 2020 results on Apr 30. In the last reported quarter, the leading alcohol company delivered a positive earnings surprise of 34.2%. Moreover, it delivered a positive earnings surprise of 4.7%, on average, over t